ArticleEmerging infectious diseases2018
Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab.
Article in Emerging infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.Pharmacological reviews · 2021Pooled it
- Trial
- Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a narrative review.Frontiers in pharmacology · 2026Review
- Invasive Meningococcal Disease in a Patient With Complement 7 Deficiency.Journal of general and family medicine · 2025Article
- Meningococcal Vaccination in the United States: Past, Present, And Future.Paediatric drugs · 2025Review
- Performance Comparison of Two In-House PCR Methods for DetectingDiagnostics (Basel, Switzerland) · 2025Article
- Learning from inborn errors of immunity and secondary immune deficiencies about vaccine immunogenicity, efficacy, and safety.Clinical and experimental immunology · 2025Review
- Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy.Children (Basel, Switzerland) · 2024Article
- The Diverse Spectrum of Invasive Meningococcal Disease in Pediatric and Adolescent Patients: Narrative Review of Cases and Case Series.Infectious diseases and therapy · 2024Review
- The genomic epidemiology ofThe Lancet regional health. Western Pacific · 2024Article
- Characterisation and Immunogenicity ofFrontiers in immunology · 2024Article
- Non-serogroupableIDCases · 2023Article
- Non-capsulatedFrontiers in immunology · 2023Review
- Limitation ofJournal of clinical microbiology · 2022Article
- Review
- Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort.Journal of nephrology · 2022Article
- Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018.Vaccine · 2022Article
- Detection of the United StatesEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020Article
- Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease.The Journal of infection · 2020Article
- Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database.Drug, healthcare and patient safety · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Patients receiving eculizumab have an increased risk for meningococcal disease, but most reported cases are attributable to encapsulated meningococcal strains. We describe a case in which a nongroupable meningococcal strain, which rarely causes disease in healthy persons, caused fatal disease in an eculizumab recipient despite meningococcal vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.